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SUMMARY
A putative synthetic vaccine for foot-and-mouth disease (FMDV 15) has proved less successful in a
host species, cattle, than predicted by results in a small-animal model. Possible reasons for this
include non-recognition by T cells influenced by major histocompatibility complex (MHC)-linked
immune response gene control. It is now possible to type for human leucocyte antigen (HLA) DR-like
bovine MHC (BoLA) class II polymorphisms with a one-dimensional isoelectric focusing (IEF)
technique. Using this method 14 unrelated cattle were selected with eight different BoLA class II IEF
types. After immunization with FMDV15, 13 cattle generated a T-cell response to FMDV15.
However, the fine specificity and magnitude of the response was related to BoLA class II type. The
non-response by one animal and low response by two other animals were associated with two of the
BoLA class II types. Response to the region 149-158 was immunodominant and animals which did
not respond to this region had low responses to the whole peptide. Using FMDV-specific T-cell lines
five BoLA class II types associated with responder animals were able to present FMDV15 in anMHC
class II-restricted fashion, indicating that this peptide is capable of binding to different MHC class II
molecules and may account for the broad response observed. The restriction patterns of the lines
indicated that the TEF method does not distinguish all functional polymorphisms. At least two of the
IEF-defined types could each be split into two distinct specificities and revealed that the three sets of
animals with identical IEF types in fact expressed distinct restriction elements.
INTRODUCTION
Synthetic peptide vaccines have been proposed as alternatives to
conventional vaccines because of the limitations of the latter.
However, the antigenic simplicity of synthetic peptides leads to
possible constraints on the design of effective synthetic vaccines,
including the requirement for linked T- and B-cell epitopes as
well as recognition of T-cell epitopes by all major histocompati-
bility complex (MHC) haplotypes. However, although MHC-
linked immune response (Ir) gene effects have been demon-
strated in an inbred mouse model with simple antigens, the
importance of MHC polymorphism in the recognition of
antigen, in a relevant outbred species such as cattle, is unclear.
Neutralizing antibody and protection are associated with
two distinct regions of the VP 1 capsid protein of the 01
Kaufbeuren strain of foot-and-mouth disease virus (FMDV).'"2
A putative vaccine antigen (FMDV15) which comprises these
two regions, 141-158 and 200-213, linked with Pro-Pro-Ser and
having Cys-Cys and Pro-Cys-Gly at the N-terminus and C-
Correspondence: Dr E. J. Glass, AFRC Institute of Animal
Physiology and Genetics Research, Edinburgh Research Station,
Roslin, Midlothian EH25 9PS, U.K.
terminus, respectively, in the absence of a carrier, has been
shown to induce a protective response in cattle.2 However, not
all animals were protected even though high serum neutralizing
titres (SNT) were generated. Also, a high dose of this peptide
was required despite being administered in Freund's complete
adjuvant. In contrast, complete protection is readily achieved in
guinea-pigs with low doses of this peptide or higher concentra-
tions of 141-160 alone.2 A high proportion of antibodies
induced by either of the peptides reacts with the virus in
neutralizing and non-neutralizing assays,3'4 indicating the effec-
tiveness of the peptides as B-cell antigens. Thus, the poorer
response of cattle may relate to T-cell recognition influenced by
MHC class 1I-linked Ir gene products. Indeed, Ir gene regula-
tion of the 141-160 antibody response has been reported in
mice.5
An obstacle to more relevant studies in cattle has been the
inability to distinguish polymorphic differences in bovine MHC
(BoLA) class II molecules. This has now been resolved by the
use of an IEF method, at least as far as products from a DR-like
locus.6 We have shown that these products function as restric-
tion elements.7 In this paper we have investigated bovine T-cell
recognition of FMDV1 5 and related peptides and demonstrate
MHC class II restriction in a natural host for FMDV.
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MATERIALS AND METHODS
Peptides
Peptides were prepared by solid-phase synthesis' and corre-
spond to VPI sequences ofFMDV strain 01K (Type 0, subtype
1, strain Kaufbeuren9). Peptides which combine discontinuous
regions of the protein (e.g. FMDV15) were prepared in a single
synthesis. The peptides used in this study are shown in Fig. 1.
FMDV15 represents the peptide used by DiMarchi et al.2 and
consists of the 200-213 sequence and the 140-158 sequence of
VP1 coupled by a Pro-Pro-Ser spacer together with a dicysteine
at the N-terminus and Pro-Cys-Gly at the C-terminus.
FMDV19 comprises the 141-158 sequence together with Pro-
Cys-Gly at the C-terminus. FMDV1.4, 1.3 and 1.2 span regions
of the 141-158 sequence and comprise 149-160, 149-163 and
152-163, respectively. FMDV26 comprises the 200-213
sequence only. Finally, FMDV5 comprises the 141-158
sequence coupled to a different sequence of VP1, 21-40.
Source of IL-2
Human recombinant interleukin-2 (hrIL-2) was purchased from
Boehringer (Lewes, Sussex, U.K.).
Animals
Friesian (Bos taurus) castrated male or female cattle from the
research station's herd were used for this study. All the animals
were clinically normal and over 6 months of age. For immuniza-
tion 14 castrated male cattle between 9 months and 12 months
were chosen.
Immunization
The animals were immunized subcutaneously with 1 mg
FMDVI5 (first immunization, Week 0), 0 2 mg FMDV15
(second immunization, Week 13) and 1 mg FMDV5 (third
immunization, Week 25) in 1: I ratio of saline and non-
ulcerative Freund's incomplete adjuvant (NUFA), courtesy of
Mr Brian D. Morris, Guildhay antisera, University of Surrey,
U.K.
Preparation ofperipheral blood mononuclear cells (PBMC)
Peripheral blood was collected just before immunization and at
varying times thereafter. PBMC were separated on Ficoll-
FMDV peptides
200 213 141 158
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Figure 1. Peptides derived from FMDV protein VP1.
Hypaque (Pharmacia, Uppsala, Sweden) as previously des-
cribed'0 and were resuspended in RPMI-1640 supplemented
with 25 mm HEPES, 2 mm glutamine, 10% foetal calf serum
(FCS), 5 x 10-5 M 2-mercaptoethanol and 50 yig/ml gentamycin
(Gibco, Paisley, Renfrewshire, U.K.) (complete medium).
Generation ofFMDV15-specific BoCD4+ cell lines
The generation and growth requirements of these lines is similar
to those for ovalbumin, as described elsewhere,"I and are briefly
as follows. PBMC from animals immunized with FMDV15,
which responded in antigen-dependent proliferation assays,'2
were selected for the generation of BoCD4+ lines, following the
method of Kimoto & Fathman.'3 After 7 days culture in the
presence of FMDV15 (1 ,ug/ml), a blast-enriched population
was obtained from the proliferating PBMC by separation on a
discontinuous Percoll gradient.'4 The T-cell blasts were then
alternatively cultured in antigen and irradiated PBMC (5000
rads) or hrIL-2 at weekly intervals. After the third in vitro
antigen restimulation, the lines were tested or frozen. Resusci-
tated lines gave similar results to those tested immediately. The
phenotype of these cell lines was similar to those described
previously." They were >90% BoCD4+ as assessed by the
monoclonal antibody (mAb) IL-Al l (this mAb was a kind gift
from Dr A. J. Teale, ILRAD, Nairobi, Kenya, and detects the
bovine CD4 equivalent).'5 They required autologous MHC
class lI-positive antigen-presenting cells (APC) for antigen-
specific proliferation. No proliferation to an unrelated antigen
(ovalbumin) was observed. Background counts were usually less
than 200 c.p.m. and the optimal dose ofFMDV15 was 1 g/ml,
which was the concentration employed in the experiments
reported here.
Proliferation assays
These were essentially as described elsewhere. 11,12 Briefly, PBMC
(2 x 105/well), or T-cell lines (1 x 104/well) together with irra-
diated PBMC (6 x 104/well) (5000 rads), were incubated with
antigen, and cell proliferation measured after 5 days or 3 days,
respectively, by a final 6-hr pulse with [3H]thymidine (Amer-
sham International, Amersham, Bucks, U.K.) and uptake
assessed by liquid scintillation counting.
BoLA class I typing
A micro-lymphocytotoxicity test, as described by Spooner et
al.,'6 was used to detect all of the internationally agreed
workshop specificities.'7 Other sera detecting specificities not yet
agreed internationally were given an Ed prefix. All specificities
behaved as alleles of a single class I locus.
One-dimensional isoelectricfocusing (IEF) -BoLA class II typing
IEF and immunoprecipitation of BoLA class II antigens were
carried out according to the method of Joosten et al.6 using a
rabbit anti-human HLA-DR antiserum (this antiserum was a
kind gift from Dr H. Ploegh, The Netherlands Cancer Institute,
The Netherlands) which precipitates BoLA class II molecules.
So far, we can detect 13 distinct banding patterns for the fl-chain
with two bands per haplotype; cx-chains appear to be mainly
non-polymorphic. The patterns are designated EDFI-EDF13
(E for Edinburgh, D in analogy to the human HLA class II
system, and F for focusing).7
40 141
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Statistics
Results were compared using the Student's t-test.
RESULTS
The peptides used in this study are shown in Fig. I and were
tested in the range 0-01-10 yg/ml. Proliferative responses by
PBMC were analysed repeatedly from Week 1 to Week 55 after
priming (followed by secondary and tertiary immunizations). It
should be noted that prior to immunization none of the animals
showed any response to FMDV1 5.
Recognition of FMDV15
Although the response to FMDV15 varied between animals,
FMDV15 was immunogenic in 13 out of the 14 animals
(Table 1). Peak proliferative responses were observed between 5
and 10 weeks after the first and second immunization (Fig. 2).
Responses by T cells from animals 1, 2, 4 and 5 remained high
throughout the second immunization period, whereas animals
3, 6, 7, 10 and 11 had sharp peaks which declined rapidly. After
the third immunization responses were maintained by animals
1-9 up to the end of the experiment, whereas animals 10-13
showed lower responses which declined to low levels by Week
55. Nonetheless, animals 10-13 did show significant responses
at a higher dose ofFMDV I 5 (1 0 pg/ml) (Table 1). Animal 14, on
the other hand, did not respond even after the third immuniza-
tion and even with the highest dose of FMDV1 5 employed (10
Yg/ml).
The responding cells were mainly BoCD4-+ T cells, as
assessed by FACS analysis (results not shown). Also, responses
to FMDV 15 by nylon wool-purified T cells (containing > 90%
T cells and < 1 O/) macrophages or B cells)'0 together with
autologous accessory cells exactly parallelled those with
untreated PBMC (results not shown).
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Figure 2. Time-course of proliferative responses by T cells from all 14
animals to FMDVI5 (I iig/ml) after each immunization. The arrows
indicate the time-points for each immunization. (a) Responses by T cells
from animals I (-),2 (A),9 (-) and 12 (0). (b) Responses by T cells from
animals 3 (0), 4 (A), 5 (-) and 13 (0). (c) Responses by T cells from
animals 6(-), 7 (-) and 10 (-). (d) Responses by T cells from animals 8
(0), 11 (A) and 14 (-).
Table . Peak response toFMDV15,19 and 1.2, 1.3, and 1.4 after the 3rd
immunization
FMDV peptide* Ac.p.m. x 10-3
Donor MHC class II MHC class 1 15 19 1.2 1.3 1.4
1 3, 7 wl l, w20 87 80 79 81 91
2 2,6 wlO,Ed99 108 30 12 12 13
3 7, 8 w 1,w14 67 61 2 8 26
4 4, 6 wIO, w15 67 42 0 0 -4
5 4, 6 w15, w18 41 40 2 5 4
6 2, 7 w13, Ed99 38 21 7 0 8
7 6, 8 w10? w 1 42 13 7 8 7
8 4, 7 wlO, w14 35 38 1 3 3
9 3, 7 wl l, w32 45 26 1 9 14
10 6,8 w1O,- 19 5 0 0 0
11 2, 5 w32,Ed99 34 14 1 0 -1
12 5, 6 wlO, w32 34 27 -1 -2 1
13 8, 11 w14,w18 4 10 0 0 0
14 5, 11 w18,- 2 1 0 0 0
* Peptide conc.' was 10 pg/ml.
Ac.p.m.=c.p.m. of test-c.p.m. with medium alone.
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Figure 3. Proliferative responses by T cells from animals I (EDF3, 7),
2 (EDF2, 6), 3 (EDF7, 8), and 9 (EDF3, 7) (a, d, c, and b, respectively)
to FMDV peptides at Week 33. (0) FMDV15; (M) FMDV19;
(E) FMDV1.2; (0) FMDVI.3; (A) FMDVl.4; (A) FMDV26. Ac.p.m.,
c.p.m. in the presence of antigen-c.p.m. with medium alone. SD were
< 10o%.
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Figure 4. Proliferative responses by FMDV1 5-specific T-cell lines
derived from animals I (EDF3, 7), 2 (EDF2, 6), 8 (EDF4, 7), and 9
(EDF3, 7) (a, b, c and d, respectively) to FMDV 1 5(1(Ig/ml) with a panel
of APC. EDF (BoLA class II) types of the panel of APC donors are
shown.
Immune responses to regions of FMDV15
All 13 of the animals responding to FMDV 15 also responded to
the 141-158 sequence (FMDV19) (Table 1). Figure 3 shows
typical dose-responses by four responder animals. All four
animals responded significantly to FMDV15 down to 0-01 jig/
ml (P 0-01). Proliferation to FMDV19 was essentially similar
to FMDV15 by PBMC from animals 1, 3, and 9 (Fig. 3a, c, b,
respectively), whereas a markedly lower, though still significant,
response to FMDV19 was observed with animal 2 (Fig. 3d)
(Ps 0-05 at 0-1 ,ug/ml). Of the 14 animals tested only one animal,
3, responded consistently to a peptide comprised of the 200-213
sequence alone (FMDV26) (Fig. 3c) (PA 0-02 at 1 pig/ml).
To analyse the T-cell recognition of the 141-158 region more
fully, three smaller peptides containing this sequence were
tested-FMDV1.2 (152-163), FMDV1.3 (149-163) and
FMDV1.4 (149-160). Of the 13 responder animals, eight
(animals 1-3 and 5-9) responded to one or all of these peptides
(Table 1) (P.0 05). Six animals (4, 10-14) did not respond to
the three shorter peptides, FMDV1.2, 1.3 or 1.4 (Table 1). With
the exception of animal 4, this group had low or non-responses
to FMDV1 5 (Fig. 2). The magnitude of response to the smaller
peptides was lower than that observed to FMDV1 5 (Table 1 and
Fig. 3). Even at the highest dose employed, 10 Mg/ml, the
response to these three peptides was usually less than that seen at
0-1 jig/ml of FMDV15 (Fig. 3).
Bovine MHC (BoLA) class II influence on bovine T-cell recogni-
tion of FMDV15
Responsiveness. All EDF5- and/or EDFl 1-positive animals
had low responses to FMDV15 and did not respond to the
shorter peptides. Animal 14 possessed both of these haplotypes
and was the only animal which did not respond at all to
FMDV15.
All EDF3- and/or EDF7-expressing animals responded to at
least one of the three shorter peptides. However, the remaining
EDF types tested, i.e. EDF2, 4, 6 and 8, were found in both the
responder and non-responder groups for the shorter peptides.
Since the animals were heterozygous, it was not possible to
determine directly if all of the EDF haplotypes in the responder
group were capable ofpresenting FMDV1 5. Furthermore, three
sets of animals (1 and 9; 4 and 5; 7 and 10) had identical EDF
haplotypes but responded to the peptides differently, suggesting
that not all restriction elements are distinguished by the IEF
method. To address these issues, T-cell lines were established
from some of the responder animals. To date no FMDV15-
specific T-cell lines have been established from the low-
responder group (animals 10-14).
MHC class II restriction. The T-cell lines were > 90%
BoCD4+ and required accessory cells together with antigen for
proliferation (results not shown). Their restriction patterns were
analysed using a panel of defined APC (Fig. 4). None ofthe lines
responded to any of the panel ofAPC in the absence of antigen.
All positive reactions with each cell line were highly significantly
different from their controls (P<0 001). Only APC expressing
EDF types in common with the individual cell lines were able to
present FMDV15 with one exception-the T-cell line derived
from animal 8 (EDF4, 7) proliferated to FMDV15 with APC 15
(EDF2, 9) (Fig. 4c). However, not all APC which shared EDF
types with the cell lines were able to present FMDV15. Thus
lines 1 and 9 (both EDF3, 7) reacted to all APC expressing
EDF7 (Fig. 4a, d) but only line 1 reacted to APC 20 (EDF3, 4).
Cell line 2 (EDF2, 6) reacted strongly with several EDF6-
expressing APC, i.e. APC 5, 7, 12 and 19, but was not stimulated
by APC 4, 10 or 18 (Fig. 4b).
DISCUSSION
This report investigates bovine T-cell recognition of a putative
vaccinal peptide, FMDV15, in relation to MHC class II type.
Friesian cattle were used and thus were of the same breed as the
animals used in the original study on FMDV15.2 Moreover,
they were unrelated and were selected to minimize as many
background effects as possible, e.g. they were all male and of a
similar age. The composition ofBoLA class II types in the group
selected (Table 1) reflected the most frequent haplotypes in our
herd (R. A. Oliver, unpublished observations). Animals were
immunized with I mg uncoupled FMDV15 in FIA. This dose is
of the order previously shown to induce a strong immune
response in cattle.2 FMDV15 contains T-cell epitope(s) which
are recognized by T cells from 13 out of 14 cattle. The cattle were
heterozygous for EDF type and thus expressed at least two
potential restriction elements for presentation of FMDV15.
Furthermore, the broad response to this peptide suggests that it
is capable of binding to several different bovine MHC class II
molecules. With most animals, FMDV19 elicited essentially
similar responses to FMDV1 5, indicating that the region 140-
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158 contained major T-cell determinants for cattle. This region
is a focus for T cells from other species, including laboratory
mice and guinea-pigs. 18 It contains structural features associated
with T-cell epitopes, including amphipathic a-helices and a
Rothbard predicted epitope'9 154-157 (KVAR).20 Smaller pep-
tides containing this sequence were recognized by eight animals.
The magnitude of response was considerably lower with these
peptides except with animal 1, suggesting that the removal of C-
terminal Pro-Cys-Gly influenced the response. These shorter
peptides also did not contain the conserved Arg-Gly-Asp
(RGD) sequence, which is involved in virus attachment to cells2'
and may therefore enhance binding of the larger peptides,
FMDV15 and FMDV19, to APC. The remaining five animals
(4, 10-13) which did not respond to the shorter peptides all
recognized FMDV19 and must therefore be recognizing a T-cell
epitope which requires residues within the sequence 141-148.
Other than animal 4, these animals also had relatively low T-cell
responses to FMDV 15 (and correspondingly low responses to
FMDV19). This suggests that the region containing the Roth-
bard predicted epitope is immunodominant. As suggested by
Kojima et al.22 for whole proteins, recognition of this region
would determine the magnitude of response to the whole
peptide, FMDV1 5.
Although all three shorter peptides contained the Rothbard
predicted epitope, the sequences to either side of the epitope
appeared to influence recognition (Table 1). Of particular
interest, the addition of three residues to the C-terminus, i.e.
160-163 (FMDVI.3) reduced responsiveness by animals 3 and
9, and loss of residues 149-151 (FMDVI.2) almost totally
ablated T-cell receptor (TcR) recognition. The presence or
absence of these residues may hinder MHC class II binding or
TcR recognition, possibly through their influence on peptide
conformation,23 underlining the stringent structural require-
ments for effective peptide vaccines. The 200-213 sequence
coupled to a carrier induced very low levels of neutralizing
antibody in guinea-pigs,' whereas as a free peptide it failed to
induce anti-viral or anti-peptide antibody and to protect.24
However, when co-linearly synthesized to 141-158 it improved
the efficacy of the 141-158 peptide.2 The 200-213 sequence
contains no structures currently associated with T-cell epi-
topes,25 although a response was seen consistently with animal 3.
The 21-40 sequence, on the other hand, does contain an
epitope(s) recognized by bovine T cells.25 In order to determine
whether the 200-213 sequence played any role in the T-cell
recognition of 141-158, the third immunization was with
FMDV5, which consisted of the 141-160 sequence co-linearly
synthesized with 21-40. The majority of animals (1-9) main-
tained T-cell responses to FMDV15 and FMDV19 up to Week
55 (and indeed to Week 110, results not shown). Thus memory
T cells had been generated. However, animals 10 and 11 had low
responses which were not sustained, although they had res-
ponded to FMDV15 and to the 141-158 sequence after the
second immunization. This suggests that, for these animals, the
21-40 sequence had adversely affected the recognition of 141-
158. This may be because the 21-40 sequence alters the
conformation of the peptide, thereby affecting the binding of
141-158 to MHC molecules, or the exact epitope generated by
processing may be different. Thus the context in which an
epitope is seen may affect its recognition, as has been described
for other antigens,23'26 and has considerable implications for the
design of effective vaccines. In terms of MHC class II-linked Ir
gene effects, EDF5 and 11 may confer low responsiveness.
Animal 14 was the only animal which did not respond at all and
possessed both ofthese types. Ofthe low responder animals, 10-
13, three of these animals possessed EDF5 or EDF1 1. The poor
immunogenicity ofFMDV1 5 in these animals may be related to
the ability of these MHC alleles to bind this peptide, since
determinant selection appears to correlate with T-cell respon-
siveness.27 Alternatively, FMDVI 5 may induce an MHC-linked
Ts response. However, the low responsiveness cannot simply be
attributed to dominant suppression, since these animals res-
ponded to FMDV15, albeit at a relatively low level.
Apart from EDF3 and EDF7, which were found exclusively
in the group which responded to the shorter peptides,
FMDV1.2-1.4, the other EDF types were associated with both
the responder and non-responder groups.
T-cell lines were generated from some of the animals in the
responder group to further investigate MHC class II-linked
control of T-cell recognition ofFMDV 15. The response by these
T-cell lines confirmed that EDF2, 3, 4, 6 and 7 can present
FMDV15. Thus several different bovine class II molecules can
bind this peptide. This is in contrast to most other peptide
antigens, although 'promiscuous' binding to MHC class II
molecules has been reported for a malaria peptide28 and two
tetanus toxoid peptides.29 Nonetheless the cattle group con-
tained low responders, and variation in response to the shorter
peptides FMDV1.2-1.4 was observed. These results imply that
the interactions between peptide and different MHC class II
molecules are different. Even so, peptide binding to multiple
MHC class II molecules is promising for the development of
synthetic vaccines for outbred species.
Although the cell lines, with one exception, only responded
to FMDV15 in association with APC expressing shared IEF
types, they did not respond to every APC with common EDF
types. In particular, only cell line I and not cell line 9 (both
EDF3, 7) responded to APC 20, which apparently shared EDF3
with both cell lines. Furthermore, marked differences in the
ability of APC from the other two sets of animals with
apparently identical EDF types to present FMDV 15 to cell line
2 (through EDF6) were observed. Thus APC from animals 4
(EDF4, 6) and 7 (EDF6, 8) induced a positive response whereas,
in contrast APC 5 (EDF4, 6) and 10 (EDF6, 8) were unable to
present to cell line 2. The inability of the APC 5 to present
FMDV15 to line 2 was not due to an intrinsic defect in
presentation, since APC 5 was able to present FMDV 15 to cell
line 8 (via EDF4). Taken together these results suggest that the
IEF method does not distinguish all MHC class II haplotypes.
Either different restriction elements have identical pI points or
FMDV15 has been presented through non-DR-like restriction
elements. Whichever is the case, it provides an explanation for
the differences in T-cell response seen in Fig. 2 and Table I by the
three sets of animals, which have apparently identical EDF
haplotypes (i.e. animals I and 9; 4 and 5; 7 and 10). This is in
contrast to the presentation of another antigen, ovalbumin,
where there appears to be closer association between the EDF
types and T-cell response.7 Only one c/# product per haplotype
is detected with the IEF technique,6 whereas evidence for more
than one BoLA class II locus at the genetic level has been
reported.3032 Furthermore, patterns of reactivity with BoLA
class Il-specific alloclones also indicate that more than one
restriction element is expressed per haplotype.33 This is the
subject of further research.
598
MHC class II restricted recognition ofFMD V peptides 599
In conclusion, FMDV 15 does contain bovine T-cell epitopes
and the MHC class II type of the animal profoundly affects its
response to this peptide, both in terms of fine specificity and in
magnitude of response. Nonetheless this peptide does bind to
several different BoLA class II molecules. Current research is
investigating the relationship of the T-cell response to FMDV15
to the production of serum neutralizing antibody and protec-
tion. These results have far-reaching implications for the design
of a more effective vaccine against FMDV in cattle, and indeed
for the design of subunit vaccines for any outbred species.
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